



2100

BOX PATENT
APPLICATION

A


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

A. Transmitted Herewith are the Following:

1. Complete continuation patent application of: U.S. patent application serial no. 09/041,809 filed March 13, 1998 to BROWN, entitled PHENOSCOPE AND PHENOBASE. A preliminary amendment shall be filed within three months.
2. An application consisting of 45 pages of specification, claims and abstract and 20 sheets of formal drawings is attached.
3. A copy of the Transmittal Letter filed February 1, 2000 in parent application serial no. 09/041,809.
4. A copy of the Revocation and Power of Attorney filed February 1, 2000 in parent application serial no. 09/041,809.
5. A copy of the Statement Under 37 CFR 3.73(b) filed February 1, 2000 in parent application serial no. 09/041,809.
6. A copy of the Associate Power of Attorney filed February 1, 2000 in parent application serial no. 09/041,809.
7. The entire disclosure of the prior application, from which a copy of the declaration is supplied, is considered as being part of the disclosure of this application and is hereby incorporated by reference herein.
8. A copy of the Declaration and Power of Attorney filed in the above noted prior application is attached.
9. The prior application was assigned to Health Hero Network, Inc., by an assignment recorded at reel 9037/frame 0163
10. A Small Entity Statement was filed in the prior application. Small entity status is still proper and desired in this application.
11. A filing date in accordance with 37 C.F.R. § 1.10 is requested. The Express Mail Certificate appears below.
12. Petition and Fee for Extension of Time Under 37 C.F.R. §1.136(a).



COMPUTATION OF FEE FOR CLAIMS AS FILED

	No. Filed	No. Extra	Rate	Fee
Total Claims	29	9	\$9.00	\$81.00
Independent Claims	5	2	\$34.00	\$68.00
Basic Filing Fee			\$345.00	\$345.00
3 month Extension of Time			\$435.00	\$435.00
			Total Filing Fee	\$929.00

13. Our check No. 1635 in the amount of \$929.00 to cover the total fee as computed above is enclosed.

B. Additional Fee Charges or Credit for Overpayment


The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 501050. This authorization also hereby includes a request for any extensions of time of the appropriate length required upon the filing of any reply during the entire prosecution of this application. *A copy of this sheet is enclosed.*

Please address all communications to:

Michael S. Smith
Black Lowe & Graham^{PLLC}
816 Second Avenue
Seattle, Washington 98104
Telephone: 206.381.3300
Facsimile: 206.381.3301

Respectfully submitted,

BLACK LOWE & GRAHAM^{PLLC}



Michael S. Smith
Registration No. 39,563
Phone: 206.381.3300


EXPRESS MAIL CERTIFICATE

"Express Mail" mailing label number EL476435391US

Date of Deposit: February 2, 2000

Filed by: MSS/mjf

I hereby certify that this paper or fee is being deposited with the United States Postal Service
"Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated
above and is addressed to the Assistant Commissioner for Patents, Box Patent Application,
Washington, D.C. 20231



Michelle J. Funston

Patent Application of
Stephen J. Brown
for
Phenoscope and Phenobase

RELATED APPLICATION INFORMATION

This application is related to copending patent application 08/946,341 filed October 7, 1997 which is herein incorporated by reference.

FIELD OF THE INVENTION

This invention relates generally to the fields of genomics, bioinformatics, and drug development. More specifically, it relates to a database containing phenotypic and environmental data on groups of individuals for use in conjunction with gene sequences to identify disease-influencing genes and substances.

BACKGROUND OF THE INVENTION

The physical makeup of an individual is determined by his or her **genes**. Genes are comprised of **DNA**, which in turn consists of four **nucleotides** known as adenine(A), thymine(T), cytosine(C), and guanine(G). A particular series of nucleotides, such as ATCGATCGATCG, is known as a **gene sequence**. Each gene sequence codes for a **protein**. A defective or mutant gene sequence will not produce a working protein. The protein may not perform its purpose, the protein may carry out a different purpose than intended, too much protein may be made, too little protein may be made, or the protein may not be made at all. If the protein is essential to one or more functions of the body, disease will result.

Mutant gene sequences are either **inherited** or **acquired**. An inherited gene sequence is received from an individual's parents, while an acquired gene sequence results from an event in the individual's lifetime which changes the original gene sequence.

A classic example of an inherited mutant gene sequence is the sickle cell anemia gene. Sickle cell anemia is caused by the substitution of a single nucleotide (A to T) in the gene sequence of an individual. This single substitution results in the substitution of a single amino acid (glutamic acid to valine) in the resulting hemoglobin protein. The mutant hemoglobin protein produces crescent-shaped or sickled red blood cells in affected individuals, causing a decrease in the amount of oxygen that can be transported throughout the body. The lack of oxygen often results in kidney and heart failure, paralysis, and rheumatism, which are common symptoms of anemic individuals.

An example of an acquired mutant gene sequence is malignant melanoma, or skin cancer. Cancer results when normal cells in an individual's body either lose or gain certain functions, resulting in the unchecked growth of non-normal cells. These non-normal cells often form tumors and spread throughout the body, disrupting normal cell functions. A cancer such as malignant melanoma is caused when the original gene sequence in epidermal cells is changed or mutated by an environmental factor, such as UV radiation. Our cells contain repair mechanisms to fix such problems, but over time the gene sequences in epidermal cells acquire more and more mutations. Mutant proteins are then produced and cellular functions are disrupted. The individual then has skin cancer.

Although an individual's **environment** generally precipitates the development of cancer, many individuals have been found to have a predisposition to cancer. These individuals have gene sequences which are more likely to become mutated over a shorter

period of time. Examples of such gene sequences are the BRCA1 and BRCA2 genes. Women carrying these gene sequences have a higher probability of developing breast and ovarian cancer than women who carry normal gene sequences. Thus, although the affected women's original gene sequences may not be mutated, they are more likely to become mutated due to their sequence or location on a chromosome.

Another factor that should be considered when discussing genetic diseases is whether they are **monogenic** or **polygenic** in nature. Sickle cell anemia and cystic fibrosis are examples of monogenic diseases, as they are caused by a single gene sequence. Most types of cancer, asthma, and diabetes are examples of polygenic diseases, as they are caused by a variety of genes. Polygenic diseases are also more likely to be influenced by an individual's environment. Not surprisingly, polygenic diseases are more difficult to diagnose and treat. Thus, the use of gene sequences in developing new drugs is dependent the monogenic or polygenic nature of genetic diseases.

Typically, individuals with diseases caused by inherited or acquired gene sequences have only their symptoms treated. Diabetes patients receive insulin shots to regulate their blood glucose levels, asthma patients use inhalers to allow normal respiratory functions, and cancer patients undergo chemotherapy and radiation therapy to remove cancerous tumors. Although these treatments are often able to alleviate or eliminate the symptoms, they are unable to remove the genetic bases of the diseases.

The genetic bases of many diseases were discovered in the 1940's by scientists such as Beadle and Tatum, who discovered that each gene codes for a protein. Researchers then rationalized that study of the relevant gene sequences could lead to effective drug treatments for genetic diseases. The technology was inadequate, however, until the 1970-80's, when Boyer and Cohen

cloned DNA; Maxam, Gilbert, and Sanger figured out how to sequence DNA; and Mullis developed the polymerase chain reaction (PCR) technique to quickly amplify DNA sequences. Using genetics to find drug candidates soon became a practical option.

5

Before these techniques became available, the pharmaceutical industry's main method of finding new drugs was trial and error. Compounds that were found to mimic the body's natural compounds were tested *in vitro*, in animal models, and in clinical trials to see if they had a desirable effect in treating disease. This method is still used and has resulted in many well-known drugs, but it is expensive and time-consuming.

10

With the advent of improved genetic techniques, however, the pharmaceutical industry has begun concentrating on genetics as the most effective route to new drug discovery. Genomics companies can typically be classified into one of two groups.

15

The first group concentrates on **gene sequencing** in order to find both drug targets and drug candidates, usually in the form of proteins expressed by the gene sequences. Gene sequencing can either be in the form of random discovery, whereby genes are sequenced without regard to their functions, or in the form of targeted discovery, whereby a certain region of the genome which is tentatively associated with a disease is sequenced. In **random discovery gene sequencing**, potentially useful gene sequences are identified and assayed to determine if they can be used in drug development. One problem with random discovery gene sequencing is that the majority of the human genome contains introns, or gene sequences which do not code for proteins. One way to circumvent this problem is to sequence complementary DNA (cDNA) instead. cDNA is produced from messenger RNA (mRNA). mRNA, in turn, is transcribed from DNA and processed by certain enzymes which remove the introns. cDNA sequences thus code for un-interrupted proteins.

20

25

30

35

Targeted discovery gene sequencing is typically used with positional cloning, comparative gene expression, and functional cloning techniques, which are described in the next group.

5 The second group of genomics companies takes a more epidemiological approach by first researching families or groups of individuals having a similar disease, and then isolating the relevant genes. In this method, also known as **positional cloning**, blood samples are taken from the individuals and
10 analyzed. The blood samples contain DNA, which is studied to identify certain regions of the genome which appear to be associated with the disease. Linking a region of the genome with a disease is known as **linkage analysis** or **genetic linkage mapping**. Once a region of the genome has been identified, it is
15 sequenced via targeted discovery gene sequencing.

The second group of genomics companies also uses **comparative gene expression** to discover disease gene sequences. In comparative gene expression, mRNA from both healthy and diseased
20 tissue is isolated. The mRNA is then used to produce cDNA, which is sequenced using targeted discovery gene sequencing. The gene sequences from both the healthy and diseased tissue are then compared. In addition, the identification of genes associated with disease can be made by studying the level of
25 expression of genes in both the healthy and diseased tissue.

Another similar technique is **functional cloning**. Mutant or non-functional proteins in metabolic pathways are studied and identified. The proteins are sequenced using targeted discovery
30 gene sequencing and these sequences are used to figure out the corresponding DNA gene sequences. Once the disease gene sequences have been identified, they can be used in drug development.

35 Genomics companies in the first group include **Incyte Pharmaceuticals** (Palo Alto, California). Incyte uses random

discovery gene sequencing to produce its LifeSeq™ and LifeSeq
FL™ databases. These databases contain the sequences of
hundreds of human genes. These databases are licensed to drug
development companies who use the sequences to produce new
5 drugs. Databases covering animals (ZooSeq™), plants
(PhytoSeq™), and bacteria and fungi (PathoSeq™) are also
available. Incyte has also developed bioinformatics software,
which provides sequence analysis and data management for their
databases. In addition, Incyte offers cDNA libraries of the
10 gene sequences in their databases, which can be directly used in
drug development.

Human Genome Sciences (Rockville, Maryland) also concentrates on
random discovery gene sequencing, and has sequenced an estimated
15 90% of the 100,000 genes in the human body. In addition to
collaborating with drug development companies who use their gene
sequences, HGS also has its own drug discovery and development
division. A number of therapeutic proteins which appear
effective in animal models are under study.

Hyseq, Inc. (Sunnyvale, California) has its HyX Platform which
is capable of processing and sequencing millions of blood and
DNA samples. The HyX Platform includes DNA arrays of samples
and probes, software-driven modules, industrial robots for
25 screening DNA probes against DNA samples, and bioinformatic
software to analyze the genetic information. Through the use of
its HyX Platform, HyX believes it can carry out a variety of
techniques, such as gene identification, gene expression level
determination, gene interaction studies (for polygenic
30 diseases), and genetic mapping.

Affymetrix, Inc. (Santa Clara, California) has a GeneChip system
consisting of disposable DNA probe arrays containing gene
sequences on a chip, instruments to process the probe arrays,
35 and software to analyze and manage the genetic information in
the probe. The GeneChip system thus allows pharmaceutical and

biotechnology companies to collect gene sequences and apply them to drug development.

On the other hand, the pharmaceutical industry has a number of
5 genomics companies who first identify the genes which are likely to cause disease. After the genes are identified, they are sequenced and the gene sequences are used in drug development. Likewise, proteins implicated in disease can be identified and sequenced. The sequences can be used to discover the gene
10 sequences, which are then used in drug development.

Myriad Genetics, Inc. (Salt Lake City, Utah) targets families with a history of genetic disease and collects their genetic material in order to identify hereditary disease-causing genes.
15 Myriad is able to identify these genes by using positional cloning and protein interaction studies in combination with targeted discovery gene sequencing. Using these techniques, Myriad has been able to locate and identify eight disease-related gene sequences, including BRCA1 and BRCA2. These gene
20 sequences are used by Myriad's pharmaceutical partners to develop new therapeutics.

Another genomics company which uses disease inheritance patterns together with gene sequencing is **Sequana** (La Jolla, California).
25 Sequana uses DNA collection of individuals with inherited diseases, genotyping and linkage analysis, physical mapping, and gene sequencing to find disease gene sequences. Sequana also has a proprietary bioinformatics system which includes data mining tools to automatically sort and organize much of its
30 data. Like Myriad, Sequana has a number of alliances with drug development companies which license Sequana's gene sequences.

Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) employs a broader range of technologies than Myriad and Sequana.
35 In addition to positional cloning and targeted discovery gene sequencing, Millennium uses a number of other non-genetic

techniques. cDNA libraries are prepared from mouse tissues and expressed using rapid expression of differential gene expression (RARE) technology.. Different patterns of cDNA gene expression allow researchers to identify possible disease targets.

5 Millennium also uses functional cloning techniques in order to identify the gene sequences of interesting proteins. Once a potentially useful gene sequence has been identified, biological assays and bioinformatics are used as additional analyses.

10 **Genome Therapeutics Corporation** (Waltham, Massachusetts) uses a combination of positional cloning techniques and targeted discovery gene sequencing, as well as random discovery gene sequencing to isolate and identify disease gene sequences. In addition, Genome Therapeutics also has pathogen programs, which

15 sequence pathogen genomes. As many non-genetic human diseases result from infection by pathogens, Genome Therapeutics hopes to eliminate pathogens by developing drugs and vaccines using the pathogens' genomes.

20 **Gene Logic, Inc.** (Columbia, Maryland) has an accelerated drug discovery system which emphasizes its **restriction enzyme analysis of differentially expressed sequences** (READS) technology. READS is similar in nature to comparative gene expression technology. In READS, normal and diseased tissues

25 are compared in order to identify gene expression differences between the two. Genes which appear to be important in the diseased tissue are then analyzed. Restriction enzymes, which cut gene sequences at specific sites, are used to produce gene fragments. The gene fragments from the normal and diseased

30 tissues will differ and can be compared. Gene Logic also has a Flow-thru Chip and genomic databases, which it licenses to drug development companies.

Progenitor (Columbus, Ohio) focuses on developmental biology.

35 Growing cells and tissues are analyzed for their level of expression of certain genes. Study of growing cells and tissues

may help discover treatments for diseases characterized by abnormal cell growth, such as cancer and osteoporosis. Progenitor also uses bioinformatics, gene mapping, and gene sequencing to isolate, identify, and sequence relevant gene sequences.

OncorMed, Inc. (Gaithersburg, Maryland) has focused on the development of medical services using genetic information. OncorMed offers a number of tests for hereditary diseases such as breast and colon cancers and malignant melanoma. The medical services include measurements of replication error rates in tumors, molecular profiling of tumor suppresser genes, and gene sequencing. In addition, OncorMed has a genomics repository containing known cancer gene sequences.

U.S. Patent No. 5,642,936 issued to Evans and assigned to OncorMed describes a method for identifying human hereditary disease patterns. According to the method, data is collected on individuals having a history of disease within their families. Factors related to each disease are given weights, and the weights for each individual are summed. If the sum is above a certain predetermined threshold value, the individual is deemed to have a hereditary risk for the disease. Records from a number of individuals having a hereditary risk for a disease are collected to form a database.

The methods used by the above companies all focus on the genetic aspect of hereditary disease. Gene sequencing and positional cloning represent the two approaches generally taken. However, very little emphasis is put on the environmental aspect of hereditary disease. An individual's environment is defined as his or her physical surroundings, geographical location, diet, lifestyle, etc. For many diseases which are genetic in origin, such as most cancers, an individual's environment plays a large role in determining whether or not the individual eventually develops the disease. Some individuals who have disease gene

sequences develop diseases, while others who carry the exact same disease gene sequences do not. One purpose of collecting environmental data about individuals whose gene sequences are studied is to effectively rule out any non-genetic causes of disease. Another purpose is to discover if any individuals who are carrying disease gene sequences but who do not develop the disease have other compensatory gene sequences or factors which enable them to live disease-free.

To a certain extent, the second group of genomics companies do take into account a small amount of environmental data when they select individuals whose DNA they use for positional cloning analyses. The environmental data is usually in the form of a questionnaire or survey. However, the data is typically limited in scope to lifestyle questions, and is used only to help narrow the search for the specific disease gene in question.

In addition, most genomics companies are reluctant to share their data on individuals' with others, even those genomics companies which are studying the same gene sequences. As a result, each genomics company must gather its own data on individuals having a certain disease. For example, Sequana sent its own researcher to the island of Tristan de Cunha to study hereditary asthma, while Myriad is located in Salt Lake City to take advantage of the detailed family trees of the Mormons. For genomics companies searching for gene sequences, gathering environmental data on individuals is often an expensive, time-consuming, but necessary step. Genomics companies could potentially spend more of their time and money on actual disease gene isolation if they were able to obtain necessary environmental data from another source.

Another problem lies in the fact that when genomics companies do gather environmental data on the individuals whose gene sequences are studied, the environmental data represents only a small time frame of an individual's life. Few genomics

companies continually collect data over a long period of time, and as a result, are not able to definitively rule out certain environmental factors which may affect disease progression. In addition, such data collections are unlikely to provide leads for factors which may prohibit the formation of disease.

OBJECTS AND ADVANTAGES OF THE INVENTION

Accordingly, it is a primary object of the present invention to provide a system and method for creating a database of information about individuals' environments over a period of time. Another object of the present invention is to provide a database containing information about individuals' environments which can be used with existing genomics databases. A further object of the present invention is to provide a method of using environmental information about an individual in conjunction with the individual's genotype to find disease-influencing genes or substances. It is another object of the present invention to use the disease-influencing genes or substances to find drug candidates or drug targets.

SUMMARY OF THE INVENTION

These objects and advantages are attained by a system and method for identifying a disease-influencing gene or protein. The method includes the step of selecting individuals having a risk factor for a certain disease. Each of the individuals is provided with a remotely programmable apparatus having a user interface for communicating queries to the individuals and for receiving responses. Each apparatus also includes a communication device, such as a modem, for communicating with a server through a communication network.

Queries relating to the individuals' environment are entered into the server and transmitted from the server to each individual's remote apparatus. After the individuals' have responded to the queries, the responses are sent back to the server and organized into a database. Data mining software is

then used to distinguish the individuals into groups based on their environmental profiles. After a period of time, each group is then further divided into categories based on their disease progression. The genomes of all the individuals are then sequenced. Data mining techniques are used to find gene differences between the categories.

According to a second method of the invention, the individuals are first separated into groups according to their disease progressions. Data mining techniques are then used to further distinguish each group into categories based on the individuals' environmental profiles. The genomes of all the individuals are then sequenced, and data mining techniques are used to find gene differences between the categories.

A third embodiment of the invention provides a method for identifying disease-influencing substances. The method includes the step of selecting individuals having a risk factor for a certain disease. Each of the individuals is provided with a remotely programmable apparatus having a user interface for communicating queries to the individuals and for receiving responses. Each apparatus also includes a communication device, such as a modem, for communicating with a server through a communication network.

Queries relating to the individuals' environment are entered into the server and transmitted from the server to each individual's remote apparatus. After the individuals' have responded to the queries, the responses are sent back to the server and organized into a database. The genomes of all the individuals are then sequenced. The individuals are placed into groups based on their gene sequences. Each group is then separated into categories based on the individuals' disease progression. Data mining techniques are then used to find a disease-influencing substance between the categories of individuals by using the individuals environmental profiles.

The disease-influencing gene or substance isolated using these methods is preferably used to develop drug candidates or drug targets. Additionally, the isolation of the disease-influencing gene is preferably used to identify a corresponding disease-influencing protein, which can also be used to develop drug candidates or drug targets.

The present invention also provides a database and data processing system for storing and analyzing environmental information about individuals. The database and data processing system comprise a server for storing queries and the individuals' responses to the queries. The system also includes at least one remotely programmable apparatuses having a user interface for communicating queries to the individuals and for receiving the responses. Each apparatus also includes a communication device, such as a modem, for communicating with the server through a communication network.

The system also includes genotyping means in communication with the server for determining the individuals' gene sequences and a data mining software program accessible to the server for analyzing the individuals' gene sequences and environmental profiles. In particular, the data mining program includes: means for analyzing the responses in order to group the individuals having a similar behavioral and environmental profile, a similar disease progression, and a similar genotype; means for analyzing the responses in order to group the individuals having a similar disease progression; means for analyzing the responses in order to group the individuals having a similar genotype; and means for identifying a disease-influencing gene or substance. Alternatively, the database can be used with other genomics or bioinformatics databases and systems if the information is to be manipulated in different ways.

DESCRIPTION OF THE FIGURES

- Fig. 1 is a block diagram of a networked system according to a preferred embodiment of the invention.
- 5 Fig. 2 is a block diagram illustrating the interaction of the components of the system of Fig. 1.
- Fig. 3 is a perspective view of a remotely programmable apparatus of the system of Fig. 1.
- Fig. 4 is a block diagram illustrating the components of the apparatus of Fig. 3.
- 10 Fig. 5 is a script entry screen according to the preferred embodiment of the invention.
- Fig. 6A is a listing of a sample script program according to the preferred embodiment of the invention.
- 15 Fig. 6B is a continuation of the listing of Fig. 6A.
- Fig. 7 is a script assignment screen according to the preferred embodiment of the invention.
- Fig. 8 is a sample query appearing on a display of the apparatus of Fig. 3.
- 20 Fig. 9 is a sample prompt appearing on the display of the apparatus of Fig. 3.
- Fig. 10 is a sample report displayed on a workstation of the system of Fig. 1.
- Fig. 11A is a flow chart illustrating the steps included in a monitoring application executed by the server of Fig. 1 according to the preferred embodiment of the invention.
- 25 Fig. 11B is a continuation of the flow chart of Fig. 11A.
- Fig. 12A is a flow chart illustrating the steps included in the script program of Figs. 6A - 6B.
- 30 Fig. 12B is a continuation of the flow chart of Fig. 12A.
- Fig. 13 is a sample data table of the present invention.
- Fig. 14 is a sample completed data table of the present invention.
- 35 Fig. 15 is a flow chart illustrating a first method for identifying a gene according to the present invention.

Fig. 16 is a block diagram illustrating the method of Fig. 15.
Fig. 17 is a flow chart illustrating a second method for identifying a gene according to the present invention.
Fig. 18 is a block diagram illustrating the method of Fig. 17.
5 Fig. 19 is a flow chart illustrating a third method according to the present invention.
Fig. 20 is a block diagram illustrating the method of Fig. 19.

DETAILED DESCRIPTION

10 The invention presents a system and method for creating a database containing environmental information about an individual to be used in conjunction with the individual's gene sequences to find new drug targets and drug candidates. In a preferred embodiment of the invention, remote monitors are used
15 to collect the environmental information. It is to be understood that environmental information includes all non-genetic information about an individual, such as disease progression, diet, lifestyle, and geographical location.

20 A preferred embodiment of the invention is illustrated in Figs. 1 - 16. Referring to Fig. 1, a networked system includes a server 50 and a workstation 52 connected to server 50 through a communication network 58. Server 50 is also connected to a patient profile database 54 which stores environmental
25 information about the individuals. Server 50 is further connected to a genotyping system 56 which is capable of sequencing individuals' genomes. Patient profile database 54 and genotyping system 56 are connected to server 50 through communication network 58.

30 Server 50 and patient profile database 54 are preferably world wide web servers. Server 50 and database 54 may comprise single stand-alone computers or multiple computers distributed throughout a network. Workstation 52 is preferably a personal
35 computer, remote terminal, or web TV unit. Workstation 52

functions as a remote interface for entering in server 50 messages and queries to be communicated to the individuals.

Genotyping system 56 can be a laboratory capable of sequencing individuals' genomes, a gene sequencing chip such as the GeneChip by Affymetrix, or any other suitable genotyping system. Genotyping system 56 should be capable of transmitting information about the individuals' genomes to server 50. Communication network 58 connects workstation 52, patient profile database 54, and genotyping system 56 to server 50. Communication network 58 can be any suitable communication network, such as a telephone cable, the Internet, or cellular or wireless communication. Such communication networks are well known in the art.

The system also includes remotely programmable apparatuses 60 for monitoring individuals. Preferably, each remote apparatus 60 is used to monitor a respective one of the individuals. Alternatively, a multi-user apparatus may be used to monitor a plurality of individuals. Each remote apparatus is designed to interact with an individual in accordance with script programs received from server 50.

Each remote apparatus is in communication with server 50 through communication network 58, which is preferably the Internet. Alternatively, each remote apparatus may be placed in communication with the server via telephone cable, cellular communication, wireless communication, etc. For clarity of illustration, only two remote apparatuses are shown in Fig. 1. It is to be understood that the system may include any number of remote apparatuses for monitoring any number of individuals.

In the preferred embodiment, each individual to be monitored is also provided with a monitoring device 64. Monitoring device 64 is designed to produce measurements of a physiological condition of the individual, record the measurements, and transmit the

measurements to the individual's remote apparatus 60 through a standard connection cable 62. Examples of suitable monitoring devices include blood glucose meters, respiratory flow meters, blood pressure cuffs, electronic weight scales, and pulse rate monitors. Such monitoring devices are well known in the art.

The specific type of monitoring device provided to each individual is dependent upon the individual's disease. For example, diabetes patients are provided with blood glucose meters for measuring blood glucose concentrations, asthma patients are provided with respiratory flow meters for measuring peak flow rates, obesity patients are provided with weight scales, etc.

Fig. 2 shows server 50, workstation 52, and remote apparatus 60 in greater detail. Server 50 includes a database 66 for storing script programs 68. The script programs 68 are executed by each remote apparatus 60 to communicate queries and messages to an individual, receive responses 70 to the queries, collect monitoring device measurements 72, and transmit responses 70 and measurements 72 to server 50. Database 66 is designed to store the responses 70 and measurements 72. Database 66 further includes a look-up table 74. Table 74 contains a list of the individuals to be monitored, and for each individual, a unique individual identification code and a respective pointer to script program 68 assigned to the individual. Each remote apparatus 60 is designed to execute the assigned script program which it receives from server 50.

Figs. 3 - 4 show the structure of remote apparatus 60 according to the preferred embodiment. Referring to Fig. 3, remote apparatus 60 includes a housing 90. Housing 90 is preferably sufficiently compact to enable the remote apparatus to be handheld and carried by an individual. Remote apparatus 60 also includes a user interface for communicating queries to the individual and for receiving responses to the queries.

In the preferred embodiment, the user interface includes a display 92 and four user input buttons 98A, 98B, 98C, and 98D. Display 92 displays queries and prompts to the individual, and is preferably a liquid crystal display (LCD). The user input buttons 98A, 98B, 98C, and 98D are for entering responses to the queries and prompts. The user input buttons are preferably momentary contact push buttons. Although the user interface of the preferred embodiment includes a display and input buttons, it will be apparent to one skilled in the art of electronic devices that any suitable user interface may be used in remote apparatus 60. For example, the user input buttons may be replaced by switches, keys, a touch sensitive display screen, or any other data input device. Alternatively, the display and input buttons may be replaced by a speech synthesis/speech recognition interface.

Three monitoring device jacks 96A, 96B, and 96C are located on a surface of housing 90. Device jacks 96A, 96B, and 96C are for connecting remote apparatus 60 to a number of monitoring devices, such as blood glucose meters, respiratory flow meters, or blood pressure cuffs, through standard connection cables (not shown). Remote apparatus 60 also includes a modem jack 94 for connecting remote apparatus 60 to a telephone jack through a standard connection cord (not shown). Remote apparatus 60 further includes a visual indicator, such as a light emitting diode (LED) 100. LED 100 is for visually notifying the individual that he or she has unanswered queries stored in remote apparatus 60.

Fig. 4 is a schematic block diagram illustrating the components of remote apparatus 60 in greater detail. Remote apparatus 60 includes a microprocessor 102 and a memory 108 connected to microprocessor 102. Memory 108 is preferably a non-volatile memory, such as a serial EEPROM. Memory 108 stores script programs received from the server, measurements received from

monitoring device **64**, responses to queries, and the individual's unique identification code. Microprocessor **102** also includes built-in read only memory (ROM) which stores firmware for controlling the operation of remote apparatus **60**. The firmware includes a script interpreter used by microprocessor **102** to execute the script programs. The script interpreter interprets script commands which are executed by microprocessor **102**. Specific techniques for interpreting and executing script programs in this manner are well known in the art.

Microprocessor **102** is preferably connected to memory **108** using a standard two-wire I²C interface. Microprocessor **102** is also connected to user input buttons **98A**, **98B**, **98C**, and **98D**, LED **100**, a clock **112**, and a display driver **110**. Clock **112** indicates the current date and time to microprocessor **102**. For clarity of illustration, clock **112** is shown as a separate component, but is preferably built into microprocessor **102**. Display driver **110** operates under the control of microprocessor **102** to display information on display **92**. Microprocessor **102** is preferably a PIC 16C65 processor which includes a universal asynchronous receiver transmitter (UART) **104**. UART **104** is for communicating with a modem **114** and a device interface **118**. A CMOS switch **116** under the control of microprocessor **102** alternately connects modem **114** and interface **118** to UART **116**.

Modem **114** is connected to a telephone jack **119** through modem jack **94**. Modem **114** is for exchanging data with the server through the communication network. The data includes script programs which are received from the server as well as responses to queries, device measurements, script identification codes, and the individual's unique identification code which modem **114** transmits to server **50**. Modem **114** is preferably a complete 28.8 K modem commercially available from Cermetek, although any suitable modem may be used.

Device interface 118 is connected to device jacks 96A, 96B, and 96C. Device interface 118 is for interfacing with a number of monitoring devices, such as blood glucose meters, respiratory flow meters, blood pressure cuffs, weight scales, or pulse rate monitors, through device jacks 96A, 96B, and 96C. Device interface 118 operates under the control of microprocessor 102 to collect measurements 72 from monitoring devices 64 and to output measurements 72 to microprocessor 102 for storage in memory 108. In the preferred embodiment, interface 118 is a standard RS232 interface. For simplicity of illustration, only one device interface 118 is shown in Fig. 4. However, in alternative embodiments, remote apparatus 60 may include multiple device interfaces to accommodate monitoring devices which have different connection standards.

Referring again to Fig. 2, server 50 includes a monitoring application 76. Monitoring application 76 is a controlling software application executed by server 50 to perform the various functions described below. Monitoring application 76 includes a script generator 78, a script assignor 80, and a report generator 82. Script generator 78 is designed to generate script programs 68 from script information entered through workstation 52. The script information is entered through a script entry screen 84. In the preferred embodiment, script entry screen 84 is implemented as a web page on the server 50. Workstation 52 includes a web browser for accessing the web page to enter the script information.

Fig. 5 illustrates script entry screen 84 as it appears on workstation 52. Script entry screen 84 includes a script name field 120 for specifying the name of script program to be generated. Screen 84 also includes entry fields 122 for entering a set of queries to be answered by an individual. Each entry field 122 has corresponding response choice fields 124 for entering response choices for the query. Screen 84 further includes check boxes 126 for selecting a desired monitoring

device type from which to collect measurements, such as a blood glucose meter, respiratory flow meter, or blood pressure cuff.

Screen **84** additionally includes a connection time field **128** for specifying a prescribed connection time at which each remote apparatus executing the script program is to establish a subsequent communication link to the server. The connection time is preferably selected to be the time at which communication rates are the lowest, such as 3:00 AM. Screen **84** also includes a CREATE SCRIPT button **130** for instructing the script generator to generate a script program from the information entered in screen **84**. Screen **84** further includes a CANCEL button **132** for canceling the information entered.

In the preferred embodiment, each script program created by the script generator **82** conforms to the standard file format used on UNIX systems. In the standard file format, each command is listed in the upper case and followed by a colon. Every line in the script program is terminated by a linefeed character {LF}, and only one command is placed on each line. The last character in the script program is a UNIX end of file character {EOF}. **TABLE 1** shows an exemplary listing of script commands used in the preferred embodiment of the invention.

TABLE 1 - SCRIPT COMMANDS

Command	Description
CLS: {LF}	Clear the display.
ZAP: {LF}	Erase from memory the last set of query responses recorded.
LED: b{LF}	Turn the LED on or off, where b is a binary digit of 0 or 1. An argument of 1 turns on the LED, and an argument of 0 turns off the LED.
DISPLAY: {chars}{LF}	Display the text following the DISPLAY command.
INPUT: mmmm{LF}	Record a button press. The m's represent a button mask pattern for each of the four input buttons. Each m contains an "X" for disallowed buttons or an "O" for allowed buttons. For example, INPUT: OXOX{LF} allows the user to press either button #1 or #3.
WAIT: {LF}	Wait for any one button to be pressed, then continue executing the script program.
COLLECT: device{LF}	Collect measurements from the monitoring device specified in the COLLECT command. The user is preferably prompted to connect the specified monitoring device to the apparatus and press a button to continue.
NUMBER: aaaa{LF}	Assign a script identification code to the script program. The script identification code from the most recently executed NUMBER statement is subsequently transmitted to the server along with the query responses and device measurements. The script identification code identifies to the server which script program was most recently executed by the remote apparatus.
DELAY: t {LF}	Wait until time t specified in the DELAY command, usually the prescribed connection time.
CONNECT: {LF}	Perform a connection routine to establish a communication link to the server, transmit the patient identification code, query responses, device measurements, and script identification code to the server, and receive and store a new script program. When the server instructs the apparatus to disconnect, the script interpreter is restarted, allowing the new script program to execute.

The script commands illustrated in **TABLE 1** are representative of the preferred embodiment and are not intended to limit the scope of the invention. After consideration of the ensuing description, it will be apparent to one skilled in the art many other suitable scripting languages and sets of script commands may be used to implement the system and method of the invention.

Script generator **78** preferably stores a script program template which it uses to create each script program. To generate a script program, script generator **78** inserts into the template the script information entered in script entry screen **84**. For example, Figs. **6A - 6B** illustrate a sample script program created by the script generator from the script information shown in Fig. **5**.

The script program includes display commands to display the queries and response choices entered in fields **122** and **124**, respectively. The script program also includes input commands to receive responses to the queries. The script program further includes a collect command to collect device measurements from the monitoring device specified in check boxes **126**. The script program also includes commands to establish a subsequent communication link to the server at the connection time specified in field **128**. The steps included in the sample script program are also shown in the flow chart of Figs. **12A - 12B** and will be discussed in the operation section below.

Referring again to Fig. **2**, script assignor **80** is for assigning the script programs **68** to the individuals. The script programs are assigned in accordance with script assignment information entered through workstation **52**. The script assignment information is entered through a script assignment screen **86**, which is preferably implemented as a web page on server **50**.

Fig. **7** shows a sample script assignment screen **86** as it appears on the workstation. Screen **86** includes check boxes **134** for

selecting the script program to be assigned and check boxes 136 for selecting the individuals to whom the script program is to be assigned. Screen 86 also includes an ASSIGN SCRIPT button 140 for entering the assignments. When button 140 is pressed, the script assignor creates and stores for each individual selected in check boxes 136 a respective pointer to the script program selected in check boxes 134. Each pointer is stored in the look-up table 74 of database 66. Screen 86 further includes an ADD SCRIPT button 138 for accessing the script entry screen and a DELETE SCRIPT button 142 for a deleting script program.

Referring again to Fig. 2, report generator 82 is designed to generate a report 88 from the responses 70 and device measurements 72 received in server 50. Report 88 is displayed on workstation 52. Fig. 10 shows a sample patient report 88 produced by report generator 82 for a selected individual. Report 88 includes a graph 146 of the device measurements received from the individual, as well as a listing of the query responses received from the individual. Specific techniques for writing a report generator program to display data in this manner are well known in the software art.

The operation of the preferred embodiment is illustrated in Figs. 1 - 12. Fig. 11A is a flow chart illustrating steps included in the monitoring application executed by server 50. Fig. 11B is a continuation of the flow chart of Fig. 11A. In step 202, the server determines if new script information has been entered through script entry screen 84. If new script information has not been entered, the server proceeds to step 206. If new script information has been entered, the server proceeds to step 204.

As shown in Fig. 5, the script information includes a set of queries, and for each of the queries, corresponding responses choices. The script information also includes a selected monitoring device type from which to collect measurements. The

script information further includes a prescribed connection time for each remote apparatus to establish a subsequent communication link to the server. The script information is generally entered in the server by a healthcare provider, such as the individuals' physician or case manager. Of course, any person desiring to communicate with the individual may also be granted access to the server to create and assign script programs. Further, it is to be understood that the system may include any number of workstations for entering script generation and script assignment information into the server.

In step 204, script generator 78 generates a script program from the information entered in screen 84. The script program is stored in database 66. Steps 202 and 204 are preferably repeated to generate multiple script programs, e.g. a script program for diabetes patients, a script program for asthma patients, etc. Each script program corresponds to a respective one of the sets of queries entered through script entry screen 84. Following step 204, the server proceeds to step 206.

In step 206, the server determines if new script assignment information has been entered through script assignment screen 86. If new script assignment information has not been entered, the server proceeds to step 210. If new script assignment information has been entered, the server proceeds to step 208. As shown in Fig. 7, script programs are assigned to each individual by selecting a script program through check boxes 134, selecting the individuals to whom selected the script program is to be assigned through check boxes 136, and pressing the ASSIGN SCRIPT button 140. When button 140 is pressed, script assignor 86 creates for each individual selected in check boxes 136 a respective pointer to the script program selected in check boxes 134. In step 208, each pointer is stored in look-up table 74 of database 66. Following step 208, the server proceeds to step 210.

In step **210**, the server determines if any of the remote apparatuses are remotely connected to the server. Each individual to be monitored is preferably provided with his or her own remote apparatus which has the individual's unique identification code stored therein. Each individual is thus uniquely associated with a respective one of the remote apparatuses. If none of remote apparatuses are connected, the server proceeds to step **220**.

If a remote apparatus is connected, the server receives from the apparatus the individual's unique identification code in step **212**. In step **214**, the server receives from the apparatus the query responses, device measurements, and script identification code recorded during execution of a previously assigned script program. The script identification code identifies to the server which script program was executed by the remote apparatus to record the query responses and device measurements. The responses, device measurements, and script identification code are stored in database **66**.

In step **216**, the server uses the individual's unique identification code to retrieve from look-up table **74** the pointer to the script program assigned to the individual. The server then retrieves the assigned script program from the database **66**. In step **218**, the server transmits the assigned script program to the individual's remote apparatus through the communication network **58**. Following step **218**, the server proceeds to step **220**.

In step **220**, the server determines if a report request has been received from workstation **52**. If no report request has been received, the server returns to step **202**. If a report request has been received for a selected individual, the server retrieves from database **66** the query responses and measurements last received from the individual, step **222**. In step **224**, the server generates and displays the report **88** on workstation **52**.

As shown in Fig. 10, the report includes the query responses and device measurements last received from the individual. Following step 224, the server returns to step 202.

5 Figs. 12A - 12B illustrate the steps included in a sample script program executed by the remote apparatus. Before the script program is received, the remote apparatus is initially programmed with the individual's unique identification code and the script interpreter used by microprocessor 102 to execute
10 script programs. The initial programming may be achieved during manufacture or during an initial connection to the server. Following initial programming, the remote apparatus receives from the server the script program assigned to the individual associated with the apparatus. The script program is received
15 by modem 114 through a first communication link to the server and stored in memory 108.

In step 302, microprocessor 102 assigns a script identification code to the script program and stores the script identification
20 code in memory 108. The script identification code is subsequently transmitted to the server along with query responses and device measurements to identify to the server which script program was most recently executed by the remote apparatus. In step 304, microprocessor 102 lights LED 100 to
25 notify the individual that he or she has unanswered queries stored in the remote apparatus. LED 100 preferably remains lit until the queries are answered by the individual. In step 306, microprocessor 102 erases from memory 108 the last set of query responses recorded.

30 In step 308, microprocessor 102 prompts the individual by displaying on display 92 "ANSWER QUERIES NOW? PRESS ANY BUTTON TO START". In step 310, microprocessor 102 waits until a reply to the prompt is received from the individual. When a reply is
35 received, microprocessor 102 proceeds to step 312. In step 312, microprocessor 102 executes successive display and input

commands to display the queries and response choices on display 92 and to receive responses to the queries.

Fig. 8 illustrate a sample query and its corresponding response choices as they appear on display 92. The response choices are preferably positioned on display 92 such that each response choice is located proximate a respective one of the user input buttons 98A, 98B, 98C, and 98D. In the preferred embodiment, each response choice is displayed immediately above a respective user input button. The individual presses the button corresponding to his or her response, and microprocessor 102 stores the response in memory 108.

In steps 314 to 318, microprocessor 102 executes commands to collect device measurements from a selected monitoring device specified in the script program. In step 314, microprocessor 102 prompts the individual to connect the selected device to one of the device jacks 96A, 96B, or 96C. A sample prompt is shown in Fig. 9. In step 316, microprocessor 102 waits until a reply to the prompt is received from the individual. When a reply is received, microprocessor 102 proceeds to step 318. Microprocessor 102 also connects UART 104 to device interface 118 through CMOS switch 116. In step 318, microprocessor 102 collects device measurements from the selected device through device interface 118. The device measurements are stored in memory 108.

In step 320, microprocessor 102 prompts the individual to connect remote apparatus 60 to telephone jack 119 so that the apparatus may connect to the server at the prescribed connection time. In step 322, microprocessor 102 waits until a reply to the prompt is received from the individual. When a reply is received, microprocessor 102 turns off LED 100 in step 324. In step 326, microprocessor 102 waits until it is time to connect to the server. Microprocessor 102 compares the connection time specified in the script program to the current time output by

clock 112. When it is time to connect, microprocessor 102 connects UART 104 to modem 114 through CMOS switch 116.

In step 328, microprocessor 102 establishes a subsequent communication link between remote apparatus 60 and server 50 through modem 114 and communication network 58. If the connection fails for any reason, microprocessor 102 repeats step 328 to get a successful connection. In step 330, microprocessor 102 transmits the query responses, device measurements, script identification code, and the individual's unique identification code stored in memory 108 to the server. In step 332, microprocessor 102 receives through modem 114 a newly assigned script program from the server. The new script program is stored in memory 108 for subsequent execution by microprocessor 102. Following step 332, the script program ends.

After the individual's information has been collected via remote apparatus 60 and the script programs, the data is mined to distinguish patterns. Data mining programs are well known in the art and can be easily adapted to this system. In the preferred embodiment, the data mining program includes a data table 150, as shown in Fig. 13. Data table 150 is stored on the server and has an individual identification number field 151, name fields 152, value fields 154 corresponding to the name fields, and explanation fields 156 corresponding to the name fields and value fields. The data type is entered into name fields 152, the possible numerical values corresponding to the data type are entered into value fields 154, and brief explanations of the data types and corresponding values are entered into explanation fields 156.

The individuals' device measurements and responses to the queries are entered into data table 150 in the form of numerical values in value fields 154. The individual's identification number is entered into individual identification number field 151. An example of data table 150 in which the individuals'

information has been entered is shown in Fig. 14. Once data table 150 contains all the necessary information, the data mining program then compares the information.

5 Fig. 15 is a flowchart illustrating a first method of the present invention carried out by the server using the data mining techniques described above. In step 400, individuals having a risk factor for a disease are selected. In step 402, these individuals are queried about their behavior and
10 environment using the script programs and remote apparatuses previously described. The responses to the queries and any device measurements are received and stored by the server. Collection of the responses and device measurements can occur over any period of time, thus allowing for more accurate data.

15 After the server receives the responses and measurements, a database comprising the individuals' behavioral and environmental profiles is created in step 404. In step 406, data mining techniques are used to group individuals having
20 similar behavioral and environmental profiles. In step 408, the server determines if it is necessary to further group the individuals in order to produce smaller groups. Steps 406 and 408 can be repeated as often as necessary.

25 In step 410, each group of individuals is categorized using data mining techniques. The individuals are categorized according to their disease progressions. For example, a group of individuals can be categorized into those that have a severe disease phenotype, those that have a moderate disease phenotype, and
30 those that have a mild disease phenotype. In step 412, the server determines if it is necessary to further categorize the individuals. Steps 410 and 412 can be repeated as often as necessary.

35 In step 414, the genomes of all the individuals are sequenced by genotyping system 56. The genotypes of all the individuals are

transmitted to server 50. In step 416, data mining techniques are used to compare the genotypes of the individuals between the categories. For example, if those individuals who have a severe disease phenotype and are overweight have a certain gene sequence, while those individuals who have a mild disease phenotype and are overweight do not, it is likely the gene sequence is responsible for the severe disease phenotype. If a gene sequence is found, it is further identified in step 418. Methods of isolating and identifying gene sequences are well known in the field.

Fig. 16 is a block diagram illustrating an example of the first method of the present invention as described in Fig. 15. First individuals having a risk factor for a certain disease, such as non-insulin dependent diabetes mellitus (NIDDM), are selected, as indicated at block 422. Behavioral and environmental information from each individual is collected using the script programs and remote apparatuses. Using data mining techniques, the individuals are then grouped into overweight individuals 424 and non-overweight individuals 426. Using data mining techniques, the individuals are then categorized into overweight individuals having severe NIDDM 428, overweight individuals having mild NIDDM 430, non-overweight individuals having mild NIDDM 432, and non-overweight individuals having severe NIDDM 434.

The individuals' genotype information is then taken, as indicated at block 436, to determine the individuals' gene sequences. For example, overweight individuals with severe NIDDM have gene sequence A, overweight individuals with mild NIDDM have gene sequence B, non-overweight individuals with mild NIDDM have gene sequence B, and non-overweight individuals with severe NIDDM have gene sequence A. Data mining techniques are then used to analyze the information and come to a conclusion. In this example, data mining would conclude that the severe

NIDDM phenotype is likely related to gene sequence A, not the individual's weight.

Fig. 17 shows a flowchart illustrating a second method of the present invention carried out by the server using the data mining techniques described above. In step 500, individuals having a risk factor for a disease are selected. In step 502, these individuals are queried about their behavior and environment using the script programs and remote apparatuses previously described. The responses to the queries and any device measurements are received and stored by the server.

After the server receives the responses and measurements from the remote apparatuses, a database comprising the individuals' behavioral and environmental profiles is created in step 504. In step 506, data mining techniques are used to group together individuals having similar disease progressions. For example, a group of individuals can be grouped into those that have a severe disease phenotype, those that have a moderate disease phenotype, and those that have a mild disease phenotype. In step 508, the server determines if it is necessary to further group the individuals in order to produce smaller groups. Steps 506 and 508 can be repeated as often as necessary.

In step 510, each group of individuals created in steps 506 and 508 is categorized using data mining techniques according to the behavioral and environmental profiles of the individuals. In step 512, the server determines if it is necessary to further group the individuals in order to produce smaller groups. Steps 510 and 512 can be repeated as often as necessary.

In step 514, the genomes of all the individuals are sequenced by genotyping system 56. The genotypes of all the individuals are transmitted to the server. In step 516, data mining techniques are used to compare the genotypes of the individuals between the categories. For example, if those individuals who have a severe

disease phenotype and are overweight have a certain gene sequence, while those individuals who have a mild disease and are also overweight phenotype do not, it is likely the gene sequence, not weight, is responsible for the severe disease phenotype. If a gene sequence is found, it is further identified in step 518. Specific techniques of isolating and identifying gene sequences are well known in the field.

Fig. 18 is a block diagram illustrating an example of the second method of the present invention as described in Fig. 17. First individuals having a risk factor for a certain disease, such as NIDDM, are chosen, as indicated at block 522. Behavioral and environmental information from each individual is collected using the remote apparatuses and script programs. Using data mining techniques, the individuals are then grouped into those exhibiting severe NIDDM 524 and those exhibiting mild NIDDM 526. Using data mining techniques, the individuals are then categorized into overweight individuals having severe NIDDM 528, non-overweight individuals having severe NIDDM 530, non-overweight individuals having mild NIDDM 532, and overweight individuals having mild NIDDM 534.

The individuals' genotype information is then taken, as indicated at block 536, to determine the individuals' gene sequences. For example, individuals with severe NIDDM who are overweight have gene sequence A, individuals with severe NIDDM who are non-overweight have gene sequence A, individuals with mild NIDDM who are non-overweight have gene sequence B, and individuals with severe NIDDM who are overweight have gene sequence B. Data mining techniques are then used to analyze the information and come to a conclusion. In this example, data mining would conclude that the severe NIDDM phenotype is likely related to gene sequence A, not the individual's weight.

Fig. 19 shows a flowchart illustrating a preferred method carried out by server 50 to identify a disease-identifying

substance. In step **600**, individuals having a risk factor for a disease are selected. In step **602**, these individuals are queried about their behavior and environment using the script programs and remote apparatuses previously described. The responses to the queries and any device measurements are received and stored by the server.

After the server receives the responses and measurements from the remote apparatuses, a database comprising the individuals' behavioral and environmental profiles is created in step **604**. In step **606**, the genomes of all the individuals are sequenced, and the genotypes of all the individuals are transmitted to the server. In step **608**, individuals having the same or close genotypes are grouped together. In step **610**, data mining techniques are used to categorize together individuals having similar disease progressions. In step **612**, the server determines if it is necessary to further categorize the individuals in order to produce smaller groups. Steps **610** and **612** can be repeated as often as necessary.

In step **614**, data mining techniques are used to find a disease-influencing substance between the categories of individuals by using the individuals behavioral and environmental profiles. For example, if those individuals who have a severe disease phenotype are overweight, while those individuals who have a mild disease phenotype are not, it is likely weight is responsible for the severe disease phenotype. If such a disease-influencing substance is found, it is identified in step **618**. If no disease-influencing substance is found, the process is preferably repeated.

Fig. **20** is a block diagram illustrating an example of the method described in Fig. **19**. First, individuals having a risk factor for a certain disease, such as NIDDM, are chosen, as indicated at block **620**. Behavioral and environmental information from each individual is collected using the remote apparatuses and

script programs. The individuals' genotype information is then taken, as indicated at block 622, to determine the individuals' gene sequences. The individuals are then grouped according to their gene sequences. For example, one group may have gene sequence A, as indicated at block 624, while another group may have gene sequence B, as indicated at block 626. Using data mining techniques, the individuals are then categorized into individuals with gene sequence A having severe NIDDM 628, individuals with gene sequence A having mild NIDDM 630, individuals with gene sequence B having mild NIDDM 632, and individuals with gene sequence B having severe NIDDM 634.

Data mining techniques are further used to analyze the categories of individuals and their behavioral and environmental profiles. For example, overweight individuals 638 with severe NIDDM have gene sequence A, non-overweight individuals 640 with mild NIDDM have gene sequence A, overweight individuals 642 with mild NIDDM have gene sequence B, and non-overweight individuals 644 with severe NIDDM have gene sequence B. Data mining techniques are then used to analyze the information and come to a conclusion. In this example, data mining would conclude that the severe NIDDM phenotype is likely related to gene sequence A, not the individual's weight.

SUMMARY, RAMIFICATIONS, AND SCOPE

Although the above description contains many specificities, these should not be construed as limitations on the scope of the invention but merely as illustrations of some of the presently preferred embodiments. Many other embodiments of the invention are possible. For example, the scripting language and script commands shown are representative of the preferred embodiment. It will be apparent to one skilled in the art that many other scripting languages and specific script commands may be used to implement the invention.

Moreover, the invention is not limited to the specific applications described. The system and method of the invention have many other applications. For example, pharmaceutical manufacturers may apply the system in clinical trials to analyze
5 new drug data.

Therefore, the scope of the invention should be determined by the appended claims and their legal equivalents.

CLAIMS

What is claimed is:

1. A method for identifying a disease-influencing gene, the method comprising the steps of:
 - a) selecting individuals having a risk factor for a disease;
 - b) creating queries regarding the individuals' behaviors and environments;
 - c) storing the queries on a server;
 - d) providing each of the individuals with a remotely programmable apparatus having a user interface for communicating the queries and for receiving responses, and having communication means for communicating with the server through a communication network;
 - e) transmitting the queries from the server to each of the remotely programmable apparatuses;
 - f) transmitting the responses of the individuals to the queries from the remotely programmable apparatuses to the server;
 - g) creating a database of the individuals' behaviors and environments;
 - h) using data mining techniques to distinguish a group of individuals having similar behavioral and environmental profiles;
 - i) categorizing the group of individuals into at least two categories according to the individuals' disease progression;
 - j) determining the genotypes of the at least two categories of individuals;
 - k) using data mining techniques to find a gene difference between the at least two categories of individuals; and
 - l) identifying the disease-influencing gene.

- 1 2. The method of claim 1, wherein the disease-influencing
2 gene is of the type which reduces the risk of developing
3 the disease.
4
- 1 3. The method of claim 2, further comprising the step
2 of using the disease-influencing gene to develop a
3 drug candidate for reducing the risk of developing
4 the disease.
5
- 1 4. The method of claim 2, further comprising the step
2 of identifying a protein associated with the
3 disease-influencing gene.
4
- 1 5. The method of claim 4, further comprising the
2 step of using the protein to develop a drug
3 candidate for reducing the risk of developing
4 the disease.
5
- 1 6. The method of claim 1, wherein the disease-influencing
2 gene is of the type which increases the risk of
3 developing the disease.
4
- 1 7. The method of claim 6, further comprising the step
2 of using the disease-influencing gene to develop a
3 drug candidate for reducing the risk of developing
4 the disease.
5
- 1 8. The method of claim 6, further comprising the step
2 of identifying a protein associated with the
3 disease-influencing gene.
4
- 1 9. The method of claim 8, further comprising the
2 step of using the protein to develop a drug
3 candidate for reducing the risk of developing
4 the disease.
5

1 10. A method for identifying a disease-influencing gene, the
2 method comprising the steps of:

- 3 a) selecting individuals having a risk factor for a
4 disease;
5 b) creating queries regarding the individuals' behaviors
6 and environments;
7 c) storing the queries on a server;
8 d) providing each of the individuals with a remotely
9 programmable apparatus having a user interface for
10 communicating the queries and for receiving responses,
11 and having communication means for communicating with
12 the server through a communication network;
13 e) transmitting the queries from the server to each of the
14 remotely programmable apparatuses;
15 f) transmitting the responses of the individuals to the
16 queries from the remotely programmable apparatuses to
17 the server;
18 g) creating a database of the individuals' behaviors and
19 environments;
20 h) distinguishing a group of individuals having similar
21 disease progressions;
22 i) using data mining techniques to categorize the group of
23 individuals into at least two categories according to
24 the individuals' behavioral and environmental profiles;
25 j) determining the genotypes of the at least two categories
26 of individuals;
27 k) using data mining techniques to find a gene difference
28 between the at least two categories of individuals; and
29 l) identifying the disease-influencing gene.
30

1 11. The method of claim 10, wherein the disease-influencing
2 gene is of the type which reduces the risk of developing
3 the disease.
4

1 12. The method of claim 11, further comprising the step
2 of using the disease-influencing gene to develop a

3 drug candidate for reducing the risk of developing
4 the disease.

5
1 13. The method of claim 11, further comprising the step
2 of identifying a protein associated with the
3 disease-influencing gene.

4
1 14. The method of claim 13, further comprising the
2 step of using the protein to develop a drug
3 candidate for reducing the risk of developing
4 the disease.

5
1 15. The method of claim 10, wherein the disease-influencing
2 gene is of the type which increases the risk of
3 developing the disease.

4
1 16. The method of claim 15, further comprising the step
2 of using the disease-influencing gene to develop a
3 drug candidate for reducing the risk of developing
4 the disease.

5
1 17. The method of claim 15, further comprising the step
2 of identifying a protein associated with the
3 disease-influencing gene.

4
1 18. The method of claim 17, further comprising the
2 step of using the protein to develop a drug
3 candidate for reducing the risk of developing
4 the disease.

5
1 19. A method for identifying a disease-influencing substance,
2 the method comprising the steps of:
3 a) selecting individuals having a risk factor for a
4 disease;
5 b) creating queries regarding the individuals' behaviors
6 and environments;

- 7 c) storing the queries on a server;
- 8 d) providing each of the individuals with a remotely
- 9 programmable apparatus having a user interface for
- 10 communicating the queries and for receiving responses,
- 11 and having communication means for communicating with
- 12 the server through a communication network;
- 13 e) transmitting the queries from the server to each of the
- 14 remotely programmable apparatuses;
- 15 f) transmitting the responses of the individuals to the
- 16 queries from the remotely programmable apparatuses to
- 17 the server;
- 18 g) creating a database of the individuals' behaviors and
- 19 environments;
- 20 h) determining the genotypes of the individuals;
- 21 i) distinguishing a group of the individuals having similar
- 22 genotypes;
- 23 j) categorizing the group of individuals into at least two
- 24 categories according to their disease progressions; and
- 25 k) using data mining techniques to find a disease-
- 26 influencing substance from the behavioral and
- 27 environmental profiles between the at least two classes
- 28 of individuals.
- 29

1 20. The method of claim 19, wherein the disease-influencing

2 substance is of the type which reduces the risk of

3 developing the disease.

4

1 21. The method of claim 20, further comprising the step

2 of using the disease-influencing substance to

3 develop a drug candidate for reducing the risk of

4 developing the disease.

5

1 22. The method of claim 19, wherein the disease-influencing

2 substance is of the type which increases the risk of

3 developing the disease.

4

1 23. The method of claim 22, further comprising the step
2 of using the disease-influencing substance to
3 develop a drug candidate for reducing the risk of
4 developing the disease.

1 24. A database and data processing system for finding a
2 disease-influencing gene among individuals having a risk
3 factor for a disease, the database and data processing
4 system comprising:

- 5 a) a server for storing queries regarding the individuals'
6 behavior and environment and for storing the
7 individuals' responses to the queries;
- 8 b) at least one remotely programmable apparatus in
9 communication with the server, wherein the remotely
10 programmable apparatus comprises:
 - 11 i) a user interface for communicating the queries to
12 the individuals and for receiving the responses; and
 - 13 ii) communication means for receiving the queries from
14 the server and for transmitting the responses to the
15 server;
- 16 c) genotyping means in communication with the server for
17 obtaining the genotype of the individual; and
- 18 d) data mining means in communication with the server,
19 wherein the data mining means includes:
 - 20 i) means for analyzing the responses in order to
21 group the individuals having a similar behavioral
22 and environmental profile, a similar disease
23 progression, and a similar genotype;
 - 24 ii) means for analyzing the responses in order to
25 group the individuals having a similar disease
26 progression;
 - 27 iii) means for analyzing the responses in order to
28 group the individuals having a similar genotype;
29 and
 - 30 iv) means for identifying the disease-influencing
31 gene.

25. The system of claim 24, further comprising at least one monitoring device for producing measurements of a physiological condition of the individuals and for transmitting the measurements to the remotely programmable apparatus, wherein the apparatus further includes device interface means for receiving the measurements from the monitoring device and means for transmitting the measurements to the server.

26. The system of claim 24, further comprising means for identifying a protein associated with the disease-influencing gene.

27. A database and data processing system for use in finding a disease-influencing substance among individuals having a risk factor for a disease, the database and data processing system comprising:

- a) a server for storing queries regarding the individuals' behavior and environment and for storing the individuals' responses to the queries;
- b) at least one remotely programmable apparatus in communication with the server, wherein the remotely programmable apparatus comprises:
 - i) a user interface for communicating the queries to the individuals and for receiving the responses; and
 - ii) communication means for receiving the queries from the server and for transmitting the responses to the server;
- c) genotyping means in communication with the server for obtaining the genotype of the individual; and
- d) data mining means in communication with the server, wherein the data mining means includes:
 - i) means for analyzing the responses in order to group the individuals having a similar behavioral

22 and environmental profile, a similar disease
23 progression, and a similar genotype;
24 ii) means for analyzing the responses in order to
25 group the individuals having a similar disease
26 progression;
27 iii) means for analyzing the responses in order to
28 group the individuals having a similar genotype;
29 and
30 iv) means for identifying the disease-influencing
31 substance.

32

1 28. The system of claim 27, further comprising at least one
2 monitoring device for producing measurements of a
3 physiological condition of the individuals and for
4 transmitting the measurements to the remotely
5 programmable apparatus, wherein the apparatus further
6 includes device interface means for receiving the
7 measurements from the monitoring device and means for
8 transmitting the measurements to the server.

9

1 29. The system of claim 27, further comprising means for
2 identifying a protein associated with the disease-
3 influencing gene.

4

Phenoscope and Phenobase

ABSTRACT OF THE DISCLOSURE

5 The present invention describes a system and method of using individuals' behavioral and environmental information in conjunction with their gene sequences to find drug candidates and drug targets. Individuals designated as having a high risk for developing a particular disease are each given a remotely
10 programmable apparatus. Queries related to the individuals' behavior and environment are sent from a server to the remotely programmable apparatuses. The individuals' responses to the queries and any physiological information in the form of measurements are sent back to the server. The process of
15 collecting individuals' information can take place over a long period of time to ensure accurate data and to allow researchers to observe progression of the disease. A data mining program on the server analyzes the individuals' behavioral and environmental information, as well as their gene sequences.
20 Differences in gene sequences, or in behavioral and environmental factors between individuals who show a severe disease phenotype and those who show a mild severe disease phenotype can then be distinguished and used to develop new drug candidates, targets, or general treatments.





Fig.1

**Fig.2**




Fig. 3




Fig. 4

84

SCRIPT ENTRY SCREEN

SCRIPT NAME: **NON-INSULIN DEP DIABETES MELLITUS SCRIPT 1** 120

QUERIES

	CHOICE 1	CHOICE 2	CHOICE 3	CHOICE 4
HOW OLD WERE YOU WHEN YOU WERE DIAGNOSED WITH NIDDM?	< 20	20-30	30-40	> 40 124
ARE YOU OVERWEIGHT?	YES	NO		
WHAT IS YOUR CHOLESTEROL LEVEL?	< 200 mg/dL	200-250 mg/dL	250-300 mg/dL	> 300 mg/dL
DO YOU SMOKE?	YES	NO		

122

SELECT DEVICE TYPE(S)

126 ~ ☒ GLUCOSE METER ☐ RESPIRATORY FLOW METER ☐ BP CUFF

CONNECTION TIME: **03:00** ▽ 128

CREATE SCRIPT 130 **CANCEL** 132

Fig.5

5/20

NUMBER: 9001 {LF}

LED: 1 {LF}

ZAP: {LF}

CLS: {LF}

DISPLAY: ANSWER QUERIES NOW?
PRESS ANY BUTTON TO START {LF}

WAIT: {LF}

CLS: {LF}

DISPLAY: HOW OLD WERE YOU WHEN YOU
WERE DIAGNOSED WITH NIDDM?

<20 20-30 30-40 >40 {LF}

INPUT: OOOO {LF}

CLS: {LF}

DISPLAY: ARE YOU OVERWEIGHT?

YES NO {LF}

INPUT: OOOO {LF}

CLS: {LF}

DISPLAY: WHAT IS YOUR CHOLESTEROL LEVEL?

<200 200-250 250-300 >300
mg/dL mg/dL mg/dL mg/dL {LF}

INPUT: OOOO {LF}

CLS: {LF}

DISPLAY: DO YOU SMOKE?

YES NO {LF}

Fig.6A

6/20

INPUT: 0000 {LF}

CLS: {LF}

DISPLAY: CONNECT GLUCOSE METER
AND PRESS ANY BUTTON
WHEN FINISHED {LF}

WAIT: {LF}

CLS: {LF}

DISPLAY: COLLECTING MEASUREMENTS {LF}

COLLECT: GLUCOSE_METER {LF}

CLS: {LF}

DISPLAY: CONNECT APPARATUS TO
TELEPHONE JACK AND
PRESS ANY BUTTON
WHEN FINISHED {LF}

WAIT: {LF}

LED: 0 {LF}

CLS: {LF}

DELAY: 03:00 {LF}

DISPLAY: CONNECTING TO SERVER {LF}

CONNECT: {LF}

{EOF}

Fig.6B

SCRIPT ASSIGNMENT SCREEN

<p>AVAILABLE SCRIPTS:</p> <p><input checked="" type="checkbox"/> <u>NIDDM SCRIPT 1</u></p> <p><input type="checkbox"/> <u>NIDDM SCRIPT 2</u></p> <p><input type="checkbox"/> <u>NIDDM SCRIPT 3</u></p>	<p>PATIENTS:</p> <p><input checked="" type="checkbox"/> <u>NIDDM GROUP A</u></p> <p><input type="checkbox"/> <u>NIDDM GROUP B</u></p> <p><input type="checkbox"/> <u>NIDDM GROUP C</u></p>
<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="border: 1px solid black; padding: 5px 10px;">ADD SCRIPT</div> <div style="border: 1px solid black; padding: 5px 10px;">ASSIGN SCRIPT</div> <div style="border: 1px solid black; padding: 5px 10px;">DELETE SCRIPT</div> </div>	

Fig. 7

WHAT IS YOUR CHOLESTEROL LEVEL?

<200 mg/dL	200-250 mg/dL	250-300 mg/dL	>300 mg/dL
<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
98A	98B	98C	98D

Fig. 8

**CONNECT GLUCOSE METER
AND PRESS ANY BUTTON
WHEN FINISHED**

<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
98A	98B	98C	98D

Fig. 9

8/20

88

PATIENT REPORT

PATIENT:

LINDSEY, DAN



144

DATE OF MEASUREMENT:

MARCH 15, 1997



146

QUERY RESPONSES

HOW OLD WERE YOU WHEN YOU WERE DIAGNOSED WITH NIDDM?

30-40

ARE YOU OVERWEIGHT?

YES

WHAT IS YOUR CHOLESTEROL LEVEL?

250-300 mg/dL

DO YOU SMOKE?

NO





Fig.10

*Fig. 11A*

10/20




Fig.11B




Fig.12A

12/20





Fig. 12B


NIDDM DATA TABLE 150		
INDIVIDUAL NO: _____ 151		
<u>152</u> NAME FIELD	<u>154</u> VALUE FIELD	<u>156</u> EXPLANATION
age when diagnosed with NIDDM?	<20 = 0 20-30 = 25 30-40 = 50 >40 = 100	to determine if condition is caused by age
overweight or non-overweight?	overwt = 50 non-overwt = 0	to determine if condition is caused by weight
cholesterol level?	<200 = 0 200-250 = 25 250-300 = 50 >300 = 100	to determine if condition is caused by cholesterol level
smoking or non-smoking?	smoking = 50 non-smoking = 0	to determine if condition is caused by nicotine

Fig.13

NIDDM DATA TABLE <u>150</u>		
INDIVIDUAL NO: 64025 <u>151</u>		
<u>152</u> NAME FIELD	<u>154</u> VALUE FIELD	<u>156</u> EXPLANATION
age when diagnosed with NIDDM?	30-40 = 50	to determine if condition is caused by age
overweight or non-overweight?	overwt = 50	to determine if condition is caused by weight
cholesterol level?	250-300 = 50	to determine if condition is caused by cholesterol level
smoking or non-smoking?	non-smoking = 0	to determine if condition is caused by nicotine


Fig.14


*Fig.15*



CONCLUDE: NIDDM NOT RELATED TO
WEIGHT, LIKELY RELATED
TO GENE SEQUENCE A


Fig.16


*Fig.17*



CONCLUDE: NIDDM NOT RELATED TO
WEIGHT, LIKELY RELATED
TO GENE SEQUENCE A

Fig.18

*Fig.19*

**Fig.20**

Declaration for Patent Application and Power of Attorney

As a below named inventor, I hereby declare that my residence, post office address, and citizenship are as stated below next to my name, and that I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought on the invention described in the attached specification entitled **Phenoscope and Phenobase**.

First or Sole Inventor:	Full name:	STEPHEN J. BROWN	Citizenship:	U.S.A.	
	Residence:	1525 Nadina Street, San Mateo, CA 94402			
	Postal Address:	same as above			

I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a). I claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN APPLICATION(S)

Country	Application Number	Date of Filing	Priority Claimed Under 35 U.S.C. §119
NONE			<input type="checkbox"/> Yes <input type="checkbox"/> No

I claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing data of this application.

PRIOR U. S. APPLICATION(S)

Application No.	Filing Date	Status			
08/946,341	10/7/97	<input type="checkbox"/> Provisional	<input type="checkbox"/> Patented	<input checked="" type="checkbox"/> Pending	<input type="checkbox"/> Provisional

I hereby appoint Thomas J. McFarlane, Reg. No. 39,299, Marek Alboszta, Reg. No. 39,894, and Mark B. Floyd, Reg. No. 41,022, and Andrei Popovici Reg. No. P-42,401 as my agents with full power of substitution to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith. Direct all correspondence to:

Mark B. Floyd
 426 Lowell Avenue
 Palo Alto, CA 94301-3813
 Telephone: 650-321-6630
 Fax: 650-321-1621.

The attorney docket number for this case is: **RYA-136**.

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both under Title 18, §1001 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

INVENTOR SIGNATURE(S)

STEPHEN J. BROWN

Date

3/13/98

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant: BROWN Attorney Docket No.: HERO-1-1033
Application No.: 09/041,809 Group Art Unit: 1655
Filing Date: March 13 1998 Examiner: Marschel, A.
File: PHENOSCOPE AND PHENOBASE

TRANSMITTAL LETTER

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

A. Transmitted Herewith are the Following:

- X 1. Copy of Revocation and Power of Attorney by Assignee (1 pg)
- X 2. Copy of Statement under 37 CFR 3.73(b) (1 pg)
- X 3. Associate Power of Attorney (1 pg)

B. Additional Fee Charges or Credit for Overpayment

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 501050. This authorization also hereby includes a request for any extensions of time of the appropriate length required upon the filing of any reply during the entire prosecution of this application. *A copy of this letter is enclosed.*

C. Remarks

Pursuant to MPEP § 402, we enclose herewith a copy of the original Power of Attorney which is a Revocation and Power of Attorney with Statement Under 37 CFR 3.73(b) from a commonly assigned patent application.

Respectfully submitted,

BLACK LOWE & GRAHAM^{PLLC}



Lawrence D. Graham
Registration No.: 40,001
Direct Dial: 206.381.3300

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to attention Examiner: Ardin H. Mrschel, Art Unit 1655, Patent and Trademark Office on the date shown below.

Date: 2-1-00


Michelle J. Funston

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: BROWN, Stephen J.

Attorney Docket No: HERO-1-1033

Serial No: 09/041,809

Examiner: Marschel, A.

Filed: March 13, 1998

Title: Phenoscope and Phenobase

ASSOCIATE POWER OF ATTORNEY

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Pursuant to 37 C.F.R. §1.34 I, Lawrence D. Graham, as attorney of record, hereby appoint Michael S. Smith, Registration No. 39,563 of Black Lowe & Graham^{PLLC} with full power to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, and to receive the Letters Patent.

Please address all further correspondence relating to this application to:

BLACK LOWE & GRAHAM^{PLLC}

Lawrence D. Graham

816 Second Avenue, 3rd Floor


Seattle, Washington 98104

Telephone: (206) 381-3300

Facsimile: (206) 381-3301

Email: graham@blacklaw.com

Respectfully submitted,



Lawrence D. Graham, Reg. No. 40,001

Date: February 1, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: BROWN, Stephen J.

Attorney Docket No. HERO-1-1039

Serial No: 08/975,774

Group Art Unit: 2761

Filed: November 21, 1997

Examiner: DIXON, T.

Title: MULTI-USER REMOTE HEALTH MONITORING SYSTEM

REVOCATION AND POWER OF ATTORNEY


TO THE ASSISTANT COMMISSIONER FOR PATENTS:

Applicant Stephen J. Brown appoints the firm of Black Lowe & Graham^{PLLC} and Richard T. Black, Washington State Bar No. 20,399 and PTO Reg. No. 40,514; David A. Lowe, Washington State Bar No. 24,453 and PTO Reg. No. 39,281; Lawrence D. Graham, Washington State Bar No. 25,402 and PTO Reg. No. 40,001; and Paul Richard Brown Washington State Bar No. 19,357, members of the firm, as its attorneys with full power of substitution and revocation to prosecute this application, to transact all related business in the Patent and Trademark Office or the Courts, to rectify any act done by the last-named appointee in respect of the said application, and to receive the patent granted thereon. This appointment simultaneously revokes all previous powers of attorney.

Address all communications to:

Richard T. Black, Esq.
Black Lowe & Graham^{PLLC}
816 Second Avenue
Seattle, Washington 98104
Direct Dial: 206.381.3300
Facsimile: 206.381.3301

Date: 1/5/00


Name: Stephen J. Brown
Title: President & CEO
Health Hero Network, Inc.

The public is authorized to inspect and copy the original of this document as it appears in application serial number 08/975,774.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: HEALTH HERO NETWORK, INC.

Application No./Patent No.: 08/975,774 Filed/Issue Date: November 21, 1997

Entitled: Multi-User Remote Health Monitoring System

Health Hero Network, Inc. a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of an undivided part interest

In the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel _____ Frame _____, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Stephen J. Brown To: Raya Systems, Inc.
The document was recorded in the Patent and Trademark Office at
Reel 8835, Frame 0970, or for which a copy thereof is attached.
2. From: Stephen J. Brown To: Health Hero Network
The document was recorded in the Patent and Trademark Office at
Reel 9186, Frame 0519, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

- ☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302-302.8]

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

1/5/00
Date


Signature

Stephen J. Brown

Typed or printed name

President & CEO

Title